We evaluated 71 patients treated with allogeneic hematopoietic cell transplantation (allo-HCT) for multiple myeloma (MM). Fortythree patients (61%) received allo-HCT after the first line of therapy. Fifty-eight patients (82%) had chemosensitive disease at the time of allo-HCT. A HLA-matched related or unrelated donor was available for 68 patients (96%). Non-myeloablative or reducedintensity conditioning regimen and peripheral blood hematopoietic cells as a graft source were used in most patients. The cumulative incidence of grade II-IV acute GVHD at day +100 and chronic GVHD at 5 years was 13% (95% CI 7-23%) and 35% (95% CI 24-46), respectively. Non-relapse mortality and relapse/progression incidence at 5 years were 12% (95% CI 5-23) and 65% (95% CI 49-76), respectively. With a median follow-up in survivors of 100 months (range 16-186), the 5-year PFS and OS were 39% (95% CI 27-52) and 60% (95% CI 55-77), respectively. On multivariate analysis: age 455 years was associated with both a reduced PFS (RR 2.11, 95% CI 1.15-3.87) and OS (RR 5.53, 95% CI 2.22-13.76); chemorefractory disease at allo-HCT was associated with both reduced PFS (RR 3.09, 95% CI 1.37-7.00) and OS (RR 3.19,). At relapse, 24 patients (56%) received bortezomib, 28 (65%) lenalidomide, 11 (26%) pomalidomide, 16 (37%) donor lymphocytes infusion as part of salvage therapy after allo-HCT relapse. Median PFS from time of salvage treatment was 7 months (range 0-113 months) for bortezomib-based therapy, 14 months (range 0-79 months) for lenalidomide and 10 months (range 1-28) for pomalidomide. Allo-HCT is a feasible and effective strategy in selected patients with MM and could be an effective platform for subsequent therapies.
INTRODUCTION
The therapeutic efficacy of allogeneic hematopoietic cell transplantation (allo-HCT) against multiple myeloma (MM) depends on the graft-versus-myeloma (GVM) effect. This concept is supported by the observation that (i) GVHD is associated with enhanced disease control 1 and that (ii) donor lymphocyte infusions (DLI) can induce responses in a substantial proportion of patients. 2 The toxicity related to the transplant procedure itself, along with the availability of new and more effective alternative drugs, has caused a substantial decline in the number of allo-HCT performed on patients with MM, even if the therapeutic benefits of allo-HCT are still unique among currently available treatments for MM.
Despite the potential ability of the GVM effect to overcome the intrinsic chemoresistance of MM plasma cells, allo-HCT is still characterized by a high number of post-transplant relapses. 3 In the present study, we examined data on a large population of MM patients treated with allo-HCT and followed-up for a prolonged period of time. In addition, we performed a detailed analysis of post-transplant salvage therapies with specific reference to new drugs.
PATIENTS AND METHODS
In this retrospective study, we analyzed 71 consecutive patients affected by MM who underwent NMA/RIC allo-HCT at Fondazione IRCCS Istituto Nazionale dei Tumori (Milano) between March 2000 and May 2014. Written informed consent was obtained from all patients and donors. Approval for this retrospective analysis was obtained from the Institutional Review Board. All patients had MM diagnosis as defined by the International Myeloma Working Group criteria. 4 Salvage therapy, transplant indication and clinical management of patients were done according to contemporary institutional and international guidelines. Allo-HCT as first-line consolidation was always preceded by ASCT. Full patient characteristics are described in Table 1 .
Definitions and study end points
Durie and Salmon Staging System, International Staging System (ISS) and Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) were calculated according to published methods. 4, 5 Standard definitions were used to assess response to therapy. 4 Acute (aGVHD) and chronic GVHD (cGVHD) were graded according to NIH criteria. 6, 7 Overall survival (OS), PFS, non-relapse mortality (NRM) and progression of disease/relapse (PD/RI) were calculated as per International guidelines. 8 
Statistical analysis
OS, PFS, duration of response (DOR) and time to next treatment (TNT) were performed with the Kaplan-Meier method. Neutrophil and platelet engraftment, aGVHD, cGVHD, NRM and PD/RI were obtained with competing risk analysis. Univariate analyses were performed using the log-rank test or competing risk analysis. Acute and cGVHD were considered as time-dependent covariates. Only covariates with a Po 0.05 in the univariate analysis were incorporated in the Cox model. Associations 1 Dipartimento di Ematologia e Onco-Ematologia Pediatrica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy and among patient-, disease-and transplant-related variables and outcomes of interest were evaluated using the Cox proportional hazards regression model. None of the covariates violated the proportional hazards assumptions. For the relapsed or progressed population, OS and PFS were measured from the time of first relapse post-allo-HCT. A subset analysis of this population was performed considering the type of post-allo-HCT salvage treatment independently from its sequential order. OS, PFS, DOR, TNT and Cox proportional hazards regression analyses were performed using STATA version 13. 9 Competing risk analysis was performed with R statistical software. 10 
RESULTS

Conditioning regimen and GVHD prophylaxis
Eighty-two percent of patients received a reduced-intensity conditioning regimen while a myeloablative one was used in only 12% of cases. The most common reduced-intensity conditioning regimen (41% of patients) was fludarabine 30 mg/ m 2 from day − 6 to − 4 followed by melphalan 140 mg/m 2 at day − 2. The most used myeloablative conditioning regimen (17% of patients) was thiotepa 10 mg/m 2 at day − 6, fludarabine 30 mg/m 2 and cyclophosphamide 30 mg/m 2 from day − 5 to − 4. Donor stem cells were infused at day 0, at least 24-48 h after the completion of chemotherapy. Granulocyte CSF (5 μg/kg) was given from day +5 until sustained neutrophil recovery.
Cyclosporine+methotrexate was the preferred GVHD prophylaxis (76% of patients). In vivo T-cell depletion with ATG was performed whenever a non-related donor (7.5 mg/kg) or a non-HLA-identical-related donor (5.0 mg/kg) was used (35% of patients). Patients who used Campath (17% of patients) as part of the conditioning regimen did not use ATG even if the donor fulfilled the above features.
Engraftment and GVHD The cumulative incidences (CI) of neutrophil and platelet recovery at day +30 were 98% (95% CI 82-100) and 96% (95% CI 84-99). The CI of grade II-IV aGVHD at day +100 was 13% (95% CI 7-23). Abbreviations: ATG = antithymocyte globulin; Allo-HCT = allogeneic hematopoietic cell transplant; Auto-HCT = autologous hematopoietic cell transplant; CR = complete remission; CSA = cyclosporine; Cy = cyclophosphamide; Flu = fludarabine; HCT-CI = Hematopoietic Cell Transplant Comorbidity Index; ISS = International Staging System; Mel = melphalan; MMF = mycophenolate mofetil; MTX = methotrexate; NA = not assessed; PBSC = peripheral blood stem cell; PR = partial remission; TBI = total body irradiation; Thio = thiotepa; VGPR = very good partial remission.
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Only two patients experienced grade III-IV aGVHD at day +100. The CI of cGVHD of all grades at 5 years was 35% (95% CI 24-46). Five patients experienced severe cGVHD by NIH criteria.
NRM and relapse NRM at 1 and 5 years were 4% (95% CI 1-11) and 12% (95% CI 5-23), respectively. None of the analyzed covariates influenced NRM. Three out of seven deaths were due to GVHD while the remaining deaths were due to infectious events.
PD/RI incidences at 1 and 5 years were 3% (95% CI 0-9) and 65% (95% CI 49-76), respectively. On multivariate analysis (Table 2 ), a value of 41 for prior lines of therapy before allo-HCT was associated with an increased risk of disease relapse or progression (HR 4.24, 95% CI 1.94-9.26, Po 0.001) while the use of bortezomib before allo-HCT was associated with a risk reduction (HR 0.40, 95% CI 0.17-0.95, P = 0.039).
Response rate, PFS and OS Sixty-four patients were evaluable for response before and after transplant. The disease status before allo-HCT was 16 CR (25%), 5 very good partial remissions (VGPR, 8%), 33 PR (52%) and 10 stable disease (SD, 15%). After allo-HCT, we observed the following best responses: 26 CR (41%), 12 VGPR (19%), 19 PR (30%), 3 SD (4%). Four patients (6%) with SD pre-allo-HCT developed progression. After allo-HCT, response improved in 22 patients (34%).
A detailed description of plasmacytomas and their clinical response to allo-HCT is reported in Supplementary Table S1 .
With a median follow-up of approximately 8 years (100 months) for surviving patients, the median PFS was 24 months, and the 5-year PFS was 39% (95% CI 27-52; Figure 1a ). On multivariate analysis (Table 2) , age 455 years (HR 2.11, 95% CI 1.15-3.87, P = 0.016) and chemorefractory disease at allo-HCT (HR 3.09, 95% CI 1.37-7.00, P = 0.007) were associated with a decreased PFS. VGPR and CR were associated with a better PFS compared with PR before allo-HCT (56 vs 24 months, P = 0.0063).
The 5-year OS was 60% (95% CI 55-77; Figure 1b ) and the median OS was not reached. Variables associated with higher mortality included age 455 years (HR 5.53, 95% CI 2.22-13.76, Po 0.001), presence of plasmacytomas before allo-HCT (HR 3.51, 95% CI 1.40-8.80, P = 0.007) and chemorefractory disease at allo-HCT (HR 3.19, 95% CI 1.40-8.80, P = 0.016).
It is worth noting that both PFS and OS were not significantly different between those who received allo-HCT as first line versus as salvage therapy (Table 2) .
Post-transplantation treatments and survival Forty-three patients had MM relapse or progression post-allo-HCT. With a median follow-up of 57 months from date of first relapse for surviving patients, the 5-year OS was 35% (95% CI 17-53). On univariate analysis, age at allo-HCT 455 years, presence of plasmacytoma and chemorefractory disease before allo-HCT were associated with shorter OS (Table 3) . Since there is no standard treatment for MM relapsing or progressing after allo-HCT, patients received heterogeneous treatments. In most cases, various lines of therapy were used because of multiple relapses or disease progression (Table 4) . Twenty-four patients received bortezomib/ dexamethasone as part of salvage therapy (14 patients received bortezomib pre-allo-HCT). Patients receiving bortezomib in association with cyclophosphamide, doxorubicine or bendamustine (6 patients) were included in the analysis while patients who received bortezomib plus lenalidomide or thalidomide (7 patients) were excluded, because the relative contribution of these drugs was difficult to ascertain. As part of a clinical protocol, in the absence of disease relapse or progression, 10 patients received bortezomib/dexamethasone followed by DLI. 11 In this case, DLI were considered as the same line of therapy as bortezomib/ dexamethasone. Median PFS was 7 months (range 0-113 months; Figure 2a ), median DOR (for the 13 responders) was 10 months (median 1-111 months) and median TNT was 8 months (range 0-113 months).
Twenty-eight patients received lenalidomide/dexamethasone as part of salvage therapy (11 patients received lenalidomide preallo-HCT). Dosage of lenalidomide ranged between 5 and 25 mg daily for 3 weeks plus dexamethasone 40 mg weekly. Median PFS was 14 months (range 0-79 months; Figure 2b ), median DOR for the 12 responders was 21 months (range 2-77 months), median TNT was 14 months (range 0-79 months). No aGVHD was reported. One patient developed limited ocular cGVHD after 2 months of therapy, while a second one experienced severe eosinophilic fasciitis after 65 months of treatment. In both cases, lenalidomide was withdrawn with improvement of clinical symptoms. Of note, lenalidomide/dexamethasone treatment was started at a median of 28 months following allo-HCT (range 5-128 months). Abbreviations: Allo-HCT = allogeneic hematopoietic cell transplant; Aut-oHCT = autologous hematopoietic cell transplant; CI = confidence interval; OS = overall; RI/POD = relapse incidence/progression of disease.
Eleven patients received pomalidomide/dexamethasone as part of salvage therapy (none of them received pomalidomide before allo-HCT). One patient who received pomalidomide plus bortezomib was excluded from the analysis. Pomalidomide dosage was 4 mg daily plus dexamethasone 40 mg weekly. Median PFS was 10 months (range 1-28 months; Figure 2c ), median DOR (for the 5 responders) was 21 months (range 16-28 months) and median TNT was 10 months (range 1-28 months). Detailed results of postallo-HCT treatments are reported in Table 5 .
DISCUSSION
In our study, 1-year and 5-year NRM were 4% and 12%, respectively. Non-relapse mortality of our study compares favorably with those reported in earlier series of NMA/RIC allo-HCT in MM, in the range of 20-30%, and this is probably due to the improvement of transplant techniques and supportive care.
12-15 A low incidence of both aGVHD and cGVHD had a significant impact on NRM and may be related to the partial in vivo T-cell depletion with ATG or low-dose alemtuzumab prophylaxis performed on patients with alternative donors. 14, 16 With a median follow-up of 100 months, the median PFS was 24 months. This result compares favorably with data observed in other studies, characterized by PFS in the range of 30-35 months when allo-HCT was performed as a first-line treatment 17, 18 or 15-20 months in relapsed patients. 19, 20 Multivariate analysis revealed that age 455 years and chemorefractory disease at allo-HCT were the only factors related to a shortened PFS. Chemorefractory disease at allo-HCT is a wellknown adverse risk factor, 21 particularly in the setting of NMA/RIC transplants. This issue may be overcome by an intensive pre-allo-HCT treatment with autologous HCT 12 or new drugs. In our study, the majority of patients received a highly active pre-allo-HCT cytoreduction, and only 13 (18%) had chemorefractory disease at transplant. The chemosensitive disease group that achieved at least a VGPR before allo-HCT was associated with a prolonged PFS. Abbreviations: Allo-HCT = allogeneic hematopoietic cell transplant; Auto-HCT = autologous hematopoietic cell transplant; DLI = donor lymphocyte infusion. a This refers to the number of patients who received the drug alone and not associated with other drugs (e.g. Bortezomib).
Median OS was not reached while 5-year OS was 60%. Our results compare favorably with previous studies where 5-year OS was approximately 60% in allo-HCT used as first-line therapy 22, 23 and 30% in subsequent lines. 12 The presence of pre-allo-HCT plasmacytomas was not associated with inferior survival in our study. However, we observed that the majority of patients with pre-transplant plasmacytomas (both extramedullary and osseous) had disease relapse with plasmacytomas after allo-HCT (most of them in sites different from the pre-allo-HCT localization) (Supplementary Table S1 ). This could suggest that allo-HCT is not effective on this highly aggressive type of MM.
In multivariate analysis, allo-HCT performed after first-line treatment was the most relevant risk factor for PD/RI. This is in line with previous studies.
In Giaccone et al., 24 long-term follow-up analysis of a pivotal study comparing auto-HCT followed by NMA/RIC allo-HCT with double auto-HCT in first-line patients concluded that OS after first relapse was significantly better for the auto-allo strategy than the double auto-HCT group. In fact, at a median follow-up of 3.9 years from relapse, median OS was not reached for the allo-HCT group while it was 1.7 years for auto-HCT patients (HR 0.44, P = 0.01). Similar results were observed in the analysis of the extended follow-up of the NMAM2000 study. 25 This study enrolled newly diagnosed MM patients who were genetically randomized to undergo a single or double auto-HCT or auto-HCT followed by NMA allo-HCT. A post-hoc landmark analysis from time of first post-transplant relapse showed that 5-year OS was 50% in the auto-allo-HCT group and 27% in the auto-HCT group (P = 0.003). In both cases, authors suggested how the effectiveness of new drugs may be improved by the presence of a subclinical GVM. Inspired by this perspective, we have evaluated the impact of posttransplant salvage therapy with new drugs. Bortezomib was administered to 31 (72%) patients, thalidomide to 12 (28%), lenalidomide to 28 (65%), pomalidomide to 12 (28%), bendamustine to 8 (19%) and DLI to 16 (37%) patients (Table 4 ). In particular, ORR to bortezomib/dexamethasone was 58%, with a PFS of 7 months, and median TNT of 8 months. These data are similar to those reported by the APEX trial. 26 However, since the majority of our study population was previously exposed to bortezomib (67% of bortezomib/dexamethasone patients), it is possible to speculate that bortezomib/ dexamethasone after allo-HCT is an effective treatment for pretreated patients as well. This observation is consistent with other studies and in particular with a French retrospective analysis regarding bortezomib salvage therapy after allo-HCT, which reported a 58% ORR and a 7 months median PFS.
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In cases treated with lenalidomide/dexamethasone, we observed a 46% ORR, with a remarkable 21% of CRs, a 14 months median PFS and a 14 months median TNT. These data compare favorably with those reported in the MM-010 study, where patients treated with lenalidomide plus dexamethasone had a 60% ORR and a time-to-progression of 11.3 months. 27 Again, it is Abbreviations: DOR = duration of response; PD = progression of disease; SD = stable disease; TNT = time to next treatment; VGPR = very good partial remission.
Allogeneic transplant and novel drugs in myeloma V Montefusco et al noteworthy that 39% of these patients received lenalidomide before allo-HCT while a previous study showed that only 54% of patients respond to re-treatment with lenalidomide. 28 Interestingly, in our study pre-allo-HCT exposure to lenalidomide had no impact on PFS after allo-HCT, if compared with lenalidomide-naive patients, suggesting that allo-HCT may restore sensitivity to this drug. 29 In particular, lenalidomide is able to restore immune detection of neoplastic cells that overexpress costimulatory molecules upregulating PDL-1 such as CD40 and B7-1. 30 In the HOVON-76 trial 30 MM patients received lenalidomide 10 mg daily for 21 days in a 28-day cycle maintenance starting from a median of 3 months after upfront allo-HCT. 31 With a median of 18 days after start of lenalidomide treatment, 53% of patients developed aGVHD and 43% discontinued prematurely. Thus, the treatment was considered not feasible in this setting. In a similar study, Alsina et al. 32 designed a dose-escalating program of lenalidomide maintenance starting from 10 mg daily for 21 days in a 28-day cycle, at a median of 96 days after allo-HCT in 30 highrisk MM patients. The authors reported improvement in the response of 33% of patients. Eighteen month PFS was 63%, aGVHD was observed in 47% and cGVHD in 23% of cases. Based on these results, the authors concluded that early lenalidomide maintenance after allo-HCT is not feasible because of an increased risk of GVHD. However, Kröger et al. 33 reported 33 patients who received lenalidomide 5 mg daily for 21 days in a 28-day cycle, with a possibility of further dose escalation after the fourth cycle, starting after a median of 168 days after allo-HCT. 33 Response improvement was observed in 7% of patients, and 3-year PFS was 52%, while 28% of patients developed grade II-IV aGVHD. The authors concluded that post-allo-HCT lenalidomide has an acceptable toxicity, but GVHD triggering should be a concern.
In our study, we did not observe an increase in GVHD incidence, which may be explained by the length of the time interval between allo-HCT and the start of lenalidomide treatment (860 days). Furthermore, unlike previous studies, in our series all patients in addition to lenalidomide received dexamethasone, a drug that may have reduced immune system activation.
Pomalidomide/dexamethasone was administered to 11 patients with a response rate of 36%, a median PFS of 10 months and a median TNT of 10 months. These data compare favorably with the data from the MM-003 trial, which included MM patients with advanced disease. 34 In this study, ORR reached 32% and PFS a median of 4 months. So far, there are no data regarding pomalidomide in the post-allo-HCT setting. Interestingly, despite the well-known potential of immune system activation, 35 we did not observe an increased incidence of GVHD.
In conclusion, our study confirms the clinical utility of allo-HCT in MM patients. Improvement of transplant techniques and supportive care reduced the NRM rate. Moreover, new drugs enable better disease control before allo-HCT, thus improving long-term survival outcomes. Finally, we have observed a remarkable efficacy and tolerability of new drugs when used after allo-HCT, supporting the hypothesis that the donor's immune system could cooperate with drugs in controlling disease relapse or progression. In this perspective, it is reasonable to consider allo-HCT for young, carefully selected, high-risk patients at first relapse, in line with established guidelines. 36 
